Eli Lilly denied NYT report of schizophrenia drug Zyprexa
Eli Lilly and Company (NYSE: LLY) called the assertions in a New York Times online article ‘flat out wrong.’ A report in The New York Times that said a senior executive had encouraged the promotion of its schizophrenia drug Zyprexa for a use not approved by federal regulators. – Eli Lilly and Company (NYSE: LLY) called the assertions in a New York Times online article ‘flat out wrong.’ A report in The New York Times that said a senior executive had encouraged the promotion of its schizophrenia drug Zyprexa for a use not approved by federal regulators.